Tulathromycin Synthesis via Epoxide Rearrangement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for producing Tulathromycin, a 15-membered azalide antibiotic, face challenges such as the use of toxic benzylchloroformate, laborious chromatography for purification, the need for toxic catalytic hydrogenation, and instability of the 9a-aza position, making it difficult to scale up production safely and efficiently.
Innovation Solution
A novel process starting from erythromycin A 9-(E)-oxime involves protecting hydroxyl groups, oxidation, conversion to an epoxide, removing protecting groups, and a Beckmann rearrangement to produce the desired epoxide, which is then converted to Tulathromycin, avoiding the use of toxic reagents and improving stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If benzylchloroformate is used as protecting agent, then protection of amino group and hydroxyl group is achieved, but toxicity and carcinogenicity increase
Solution Approach 1:
The patent replaces the toxic benzylchloroformate with a safer, more benign protecting group strategy that uses less hazardous reagents. The new approach employs protecting groups that can be removed under milder conditions without requiring toxic catalysts, thereby eliminating the carcinogenicity issue while maintaining protection functionality.
Solution Approach 2:
The patent changes the chemical parameters of the protecting group system by switching from benzylchloroformate to alternative protecting groups that offer similar protection efficacy but with improved safety profiles. This parameter change includes selecting protecting groups that do not require toxic catalysts for removal and that are not classified as carcinogens.
2Manufacturing precision
If column chromatography is used for purification, then purity of intermediates and Tulathromycin is improved, but process complexity and time consumption increase
Solution Approach 1:
The patent extracts or removes the need for column chromatography by designing a synthesis route that either prevents impurity formation or enables alternative purification methods. The new process achieves high purity through crystallization or filtration steps instead of requiring complex chromatographic separations, thereby simplifying the overall purification process.
Solution Approach 2:
The patent replaces the mechanical/chromatographic separation system with a simpler purification approach. Instead of using column chromatography which requires complex apparatus and operations, the new method employs crystallization, filtration, or other simpler separation techniques that achieve equivalent or sufficient purity levels with reduced complexity.
3Reliability
If catalytic hydrogenation is used for protective group removal, then deprotection is achieved, but process time and metal contamination increase
Solution Approach 1:
The patent replaces the catalytic hydrogenation method with an alternative deprotection approach that does not require expensive metal catalysts or prolonged reaction times. The new method uses milder, faster deprotection conditions that eliminate the need for three-day hydrogenation processes and avoid metal contamination issues.
Solution Approach 2:
The patent changes the deprotection parameters by selecting protecting groups that can be removed under different, more efficient conditions. Instead of requiring catalytic hydrogenation with Pd metal over three days, the new system allows for rapid deprotection using alternative reagents or conditions that reduce time from 72 hours to a much shorter duration.
4Ease of manufacture
If 9a-aza position is left unmethylated, then synthesis simplicity is maintained, but stability of azalide backbone decreases
Solution Approach 1:
The patent applies preliminary action by methylating the 9a-aza position at an appropriate stage in the synthesis to prevent degradation. By introducing the methyl group beforehand, the stability issue is preemptively addressed without significantly complicating the overall synthesis route, as the methylation step is integrated into the existing process flow.
Solution Approach 2:
The patent segments the synthesis into distinct stages where the 9a-methylation is performed as a separate, controlled step. This segmentation allows for optimization of each step independently, ensuring that the stability-enhancing methylation is achieved without unnecessarily complicating the rest of the synthesis pathway.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process allows for a scalable and efficient production of Tulathromycin with high yield and purity, reducing the need for toxic reagents and laborious purification steps, thereby enhancing safety and industrial feasibility.
Implementation Method 1
the hydroxyl group in 4-position is oxidized
Implementation Method 2
reaction of the epoxide group with n-propylamine
Data Source
AI summary
The present invention concerns a process for the preparation of the compound of formulaThe compound of formula (1) is the key intermediate in the synthesis of some antibacterial agents of the triamilide class, such as Tulathromycin, useful to treat bacterial and protozoa infections.